Company: NCEL
Filing Date: 2025-07-29
Form Type: F-4/A
Source: 0001213900-25-068765
Chunk: 345

Company: NewcelX Ltd.
Filing Date: 2025-07-29
Form: F-4/A
Chunk 345
---
ger Agreement shall be by arbitration in New York City in front of a single arbitrator under the auspices of the American Arbitration Association. Nasdaq Capital Market Listing NLS Common Shares and traded warrants trade on Nasdaq under the symbols “NLSP” and “NLSPW”, respectively. NLS has agreed to use its reasonable best efforts to maintain its existing listing on Nasdaq, and to obtain approval for listing on Nasdaq of the securities of NLS that Kadimastem’s shareholders will be entitled to receive pursuant to the Merger. In addition, under the Merger Agreement, each party’s obligation to complete the Merger is subject to the satisfaction or waiver by each of the parties, at or prior to the Merger, of various conditions, including NLS Common Shares shall remain listed on the Nasdaq and shall not be subject to a delisting notice from Nasdaq. The notification form for the listing of NLS Common Shares to be issued in connection with the Merger shall have been accepted and approved (subject to official notice of issuance), and the Nasdaq listing application for initial listing of NLS following the Merger and of NLS Common Shares being issued pursuant to the Merger Agreement shall have been approved. 161 NLS has filed a listing of additional securities application with Nasdaq, as required by Nasdaq to effect the issuance of NLS Common Shares in connection with the Merger or upon exercise of options or warrants or other rights issued and outstanding, whether vested or unvested, to purchase Kadimastem Ordinary Shares that will be assumed by NLS in connection with the Merger. If such application is accepted, NLS anticipates that its securities will be listed on the Nasdaq following the closing of the Merger and, subject to approval of Proposals1,2,4,6,8, 12 and 13 in the NLS Meeting, will trade under NLS’s new name, NUCLEX AG under the symbols “NCEL” and “NCELW” for its Common Shares and traded warrants, respectively. Anticipated Accounting Treatment The most recent financial information available for NLS for the twelve months ended December31, 2024, has been prepared in accordance with U.S. GAAP. The most recent financial information available for Kadimastem for the twelve months ended December31, 2024 has been prepared in accordance with IFRS, as issued by the IASB. The Merger is anticipated to be accounted for using the acquisition method (